Table of Contents

+123 456 7890
+123 456 7890
info@website.com
websitename.com
P.O. Box 283 Demo
Frederick, Country

+123 456 7890
+123 456 7890
info@website.com
websitename.com
P.O. Box 283 Demo
Frederick, Country

+123 456 7890
+123 456 7890
info@website.com
websitename.com
P.O. Box 283 Demo
Frederick, Country

Introduction and Purpose

This Clinical Trial Agreement (the "Agreement") is made and entered into as of August 9, 2025, by and between DocuPal Demo, LLC, a company located at 23 Main St, Anytown, CA 90210, USA ("Sponsor"), and Acme, Inc ("ACME-1"), located at 3751 Illinois Avenue, Wilsonville, Oregon - 97070, USA ("Investigator").

Background

DocuPal Demo, LLC, the Sponsor, is engaged in the development of pharmaceutical products, including a new drug for the treatment of hypertension. ACME-1, the Investigator, possesses the expertise and resources necessary to conduct clinical trials.

Purpose

The purpose of this Agreement is to set forth the terms and conditions under which the Investigator will conduct a clinical trial (the "Clinical Trial") to evaluate the efficacy of the Sponsor's investigational drug for hypertension. This Clinical Trial will be conducted according to the protocol attached hereto as Exhibit A (the "Protocol"). This Agreement defines the responsibilities of each party involved, ensuring the Clinical Trial is conducted in compliance with all applicable laws, regulations, and ethical guidelines.

Study Overview and Objectives

The Clinical Trial is designed to assess the safety and efficacy of the Sponsor's investigational drug in treating hypertension. The study will be conducted at the Investigator's site, following the Protocol's detailed procedures. The objectives of the Clinical Trial include:

- Evaluating the drug's impact on blood pressure levels.
- Monitoring and recording any adverse events experienced by participants.
- Collecting and analyzing data to determine the drug's effectiveness.
- Ensuring the integrity and confidentiality of all collected data.

+123 456 7890
+123 456 7890
info@website.com
websitename.com
P.O. Box 283 Demo
Frederick, Country

Contractual Intent

This Agreement expresses the complete and final understanding between the Sponsor and the Investigator regarding the Clinical Trial. Both parties intend to cooperate fully and in good faith to achieve the successful completion of the Clinical Trial. This includes adhering to the Protocol, maintaining data integrity, protecting participant privacy, and complying with all regulatory requirements. This Agreement is intended to create legally binding obligations on both the Sponsor and the Investigator.

Definitions and Interpretation

Definitions

For the purposes of this Agreement, the following terms shall have the meanings set forth below:

- **Adverse Event** means any untoward medical occurrence in a patient or clinical trial subject administered a pharmaceutical product. This does not necessarily have a causal relationship with the treatment.
- **Clinical Trial** refers to a research study conducted to evaluate the safety and efficacy of ACME-1's hypertension drug, as described in the Protocol.
- **Confidential Information** includes, but is not limited to, any data, results, or other information related to the Clinical Trial that is disclosed by one party to the other, either directly or indirectly, in writing, orally, or by inspection of tangible objects. Confidential Information excludes information that is publicly available, already known to the receiving party, or rightfully received from a third party.
- **Data** encompasses all information and records generated during the Clinical Trial, including but not limited to patient data, laboratory results, and any other information collected as per the Protocol.
- **Investigator** means the qualified individual responsible for the conduct of the Clinical Trial at the Study Site.
- **Protocol** means the document describing the objectives, design, methodology, statistical considerations, and organization of the Clinical Trial. This includes any amendments or revisions made in accordance with regulatory requirements and mutual agreement of the parties.
- **Sponsor** means ACME-1, who initiates and is responsible for the Clinical Trial.

+123 456 7890
+123 456 7890
info@website.com
websitename.com
P.O. Box 283 Demo
Frederick, Country

Interpretation

The words "include" and "including" shall be construed as "including without limitation." Unless the context requires otherwise, words in the singular include the plural and vice versa. A reference to any law or regulation includes all amendments, replacements, or re-enactments of that law or regulation. The headings in this Agreement are for convenience only and do not affect the interpretation of this Agreement. This agreement shall be governed by and construed in accordance with the laws of the State of California, United States, where DocuPal Demo, LLC is located, without regard to its conflict of laws principles. Any ambiguity in this Agreement shall not be construed against the drafter. All attachments, exhibits, and appendices are incorporated into and form an integral part of this Agreement.

Study Responsibilities and Conduct

Investigator Responsibilities

The Investigator will conduct the Clinical Trial in accordance with the protocol. This includes obtaining informed consent from each subject before their participation in the Clinical Trial. The Investigator must also report all adverse events to ACME-1 promptly. The Investigator is responsible for maintaining accurate and complete records of all data. These records must include source documents, case report forms, and correspondence related to the Clinical Trial. The Investigator will ensure the safety and well-being of all subjects participating in the Clinical Trial. Furthermore, any protocol deviations must be documented and reported to ACME-1 and the relevant ethics committee. The investigator must maintain all trial-related documents and materials in a secure location. The Investigator is expected to cooperate fully with ACME-1's monitors and auditors.

ACME-1 Responsibilities

ACME-1 will provide the investigational drug required for the Clinical Trial. ACME-1 will also fund the Clinical Trial as outlined in the budget. ACME-1 is responsible for monitoring the quality of the data collected during the Clinical Trial. ACME-1 will provide the Investigator with all necessary information about the investigational drug. This information includes its properties, potential risks, and storage requirements. ACME-1 will also provide training to the Investigator and study staff on the protocol and procedures for the Clinical Trial. ACME-1 will ensure that the

+123 456 7890
+123 456 7890
info@website.com
websitename.com
P.O. Box 283 Demo
Frederick, Country

Clinical Trial is conducted in compliance with all applicable laws and regulations. ACME-1 will promptly review and address any protocol deviations reported by the Investigator. ACME-1 will provide regular updates to the Investigator on the progress of the Clinical Trial. ACME-1 will also provide support to the Investigator in the event of any adverse events or other issues that may arise during the Clinical Trial.

Data Management and Quality Assurance

Both parties will adhere to Good Clinical Practice (GCP) guidelines. This adherence ensures data integrity and subject safety throughout the Clinical Trial. ACME-1 will implement a comprehensive data management plan. This plan will cover data collection, storage, and analysis. The Investigator will ensure the accuracy and completeness of all data entered into the case report forms (CRFs). ACME-1 will conduct regular audits of the Clinical Trial site to ensure compliance with the protocol and GCP guidelines. Any findings from these audits will be communicated to the Investigator. Corrective actions will be implemented promptly. The Investigator and ACME-1 will work together to resolve any data queries or discrepancies.

Regulatory Compliance

The Clinical Trial will be conducted in compliance with all applicable laws and regulations. This includes those of the relevant regulatory authorities. The Investigator will obtain all necessary approvals from the ethics committee. ACME-1 will submit all required reports to the regulatory authorities. Both parties will maintain complete and accurate records of all regulatory submissions and approvals. The Investigator and ACME-1 will cooperate fully with any inspections or audits conducted by the regulatory authorities.

Adverse Event Reporting

The Investigator will report all serious adverse events (SAEs) to ACME-1 within 24 hours of becoming aware of them. ACME-1 will then report these SAEs to the regulatory authorities. The Investigator will also report all other adverse events to ACME-1 in a timely manner. ACME-1 will review all adverse event reports and take appropriate action. This action ensures the safety and well-being of subjects participating in the Clinical Trial. ACME-1 will provide the Investigator with guidance on how to manage adverse events.

+123 456 7890
+123 456 7890
info@website.com
websitename.com
P.O. Box 283 Demo
Frederick, Country

Financial Terms and Payment Schedule

Docupal Demo, LLC ("Docupal") and ACME-1 agree to the following financial terms for the clinical trial. All payments will be made in United States Dollars (USD).

Payment Structure

ACME-1 will compensate Docupal for services rendered according to the following schedule, which is tied to specific study milestones:

- **Patient Enrollment:** $[Amount] per patient enrolled, up to a maximum of [Number] patients.
- **Data Submission:** $[Amount] payable upon complete and accurate submission of patient data.
- **Final Report:** $[Amount] upon delivery and ACME-1's acceptance of the final clinical trial report.

Invoicing and Payment

Docupal will submit invoices to ACME-1 monthly. Each invoice will include a detailed breakdown of expenses incurred during the invoicing period. ACME-1 will remit payment within [Number] days of receipt of a valid invoice. All invoices should be sent to the address listed under client information.

Penalties and Holds

Failure to meet enrollment targets as defined in Section [Section Number] of this Agreement may result in penalties. These penalties will be calculated as [Percentage]% reduction in the per-patient enrollment fee for each [Number] days the enrollment target is not met. ACME-1 may withhold payments for unresolved data queries until satisfactory resolution is achieved. The amount withheld will be proportional to the impact of the data queries on the overall study results, as determined by ACME-1 in consultation with Docupal.

Budget Summary

The total estimated budget for this clinical trial is $[Total Amount]. This budget includes all costs associated with investigator fees, patient recruitment, data management, statistical analysis, and report writing. A detailed budget breakdown

+123 456 7890
+123 456 7890
info@website.com
websitename.com
P.O. Box 283 Demo
Frederick, Country

is provided in **Appendix A**.

Payment Timeline

The following Gantt chart illustrates the anticipated payment timeline in relation to key study milestones.



Taxes

All fees specified are exclusive of any applicable taxes, including sales, use, value-added, or other similar taxes. ACME-1 shall be responsible for the payment of all such taxes. If Docupal is required to collect any such taxes, the amount of such taxes shall be added to Docupal's invoice and paid by ACME-1.

Currency

All transactions will be conducted and settled in United States Dollars (USD).

+123 456 7890
+123 456 7890
info@website.com
websitename.com
P.O. Box 283 Demo
Frederick, Country

Audit Rights

ACME-1 shall have the right to audit Docupal's financial records related to the clinical trial to verify the accuracy of invoices and compliance with the agreed-upon budget. ACME-1 will provide [Number] days' written notice prior to conducting any such audit. The audit will be conducted during normal business hours and in a manner that does not unduly disrupt Docupal's operations.

Confidentiality and Data Protection

DocuPal Demo, LLC and ACME-1 recognize that during the term of this Clinical Trial Agreement, each party may have access to confidential information belonging to the other party. This information may include, but is not limited to, research data, patient information, business strategies, and financial details. Both parties agree to protect this information.

Confidentiality Obligations

Each party agrees to hold the other party's confidential information in strict confidence. This means that neither party will disclose confidential information to any third party without the express written consent of the disclosing party. Access to confidential information will be restricted to those employees, agents, or consultants who have a need to know the information for the purpose of fulfilling obligations under this Agreement. All such individuals will be bound by confidentiality obligations at least as protective as those contained herein. Each party will use at least the same degree of care to protect the other party's confidential information as it uses to protect its own confidential information of a similar nature, but in no event less than reasonable care.

Data Handling and Security

ACME-1, as the study sponsor, is ultimately responsible for the secure handling and storage of all clinical trial data. DocuPal Demo, LLC will implement appropriate technical and organizational measures to ensure the security and confidentiality of the data. These measures will include, but are not limited to:

- Data encryption during transmission and storage
- Access controls to restrict data access to authorized personnel only
- Regular security audits and vulnerability assessments

+123 456 7890
+123 456 7890
info@website.com
websitename.com
P.O. Box 283 Demo
Frederick, Country

- Secure data storage facilities
- Data back-up and disaster recovery procedures

Participant Privacy

Both parties are committed to protecting the privacy of clinical trial participants. All data collected from participants will be handled in accordance with applicable data protection laws, including GDPR and HIPAA. Participants will be informed of how their data will be used and their rights regarding their data. Informed consent will be obtained from all participants prior to their enrollment in the clinical trial.

Data Protection Regulations Compliance

This clinical trial will be conducted in compliance with all applicable data protection regulations, including but not limited to:

- The General Data Protection Regulation (GDPR)
- The Health Insurance Portability and Accountability Act (HIPAA)

Both parties will cooperate to ensure that all data processing activities related to this clinical trial comply with these regulations.

Data Breach Notification

In the event of a data breach involving personal data related to this clinical trial, the party discovering the breach will immediately notify the other party. ACME-1 will then be responsible for notifying affected participants and relevant regulatory authorities as required by applicable law. The notification will include information about the nature of the breach, the data affected, and the steps being taken to mitigate the harm. Both parties will cooperate to investigate the breach and implement measures to prevent future breaches.

Data Integrity

DocuPal Demo, LLC will ensure the integrity of all clinical trial data. This includes maintaining accurate and complete records, implementing quality control procedures, and validating data to ensure its reliability. Any data discrepancies or anomalies will be investigated and resolved promptly. ACME-1 will have the right to audit DocuPal Demo, LLC's data management practices to ensure compliance with this requirement.

+123 456 7890
+123 456 7890
info@website.com
websitename.com
P.O. Box 283 Demo
Frederick, Country

Intellectual Property Rights

Ownership of Data and Inventions

ACME-1 will own all data resulting from the clinical trial. ACME-1 will also own all inventions, discoveries, and improvements conceived or reduced to practice during the clinical trial. This includes, but is not limited to, all intellectual property rights related to the drug, study protocols, and any related materials.

Publication Rights

ACME-1 retains the exclusive right to use and publish the results of the clinical trial. The Investigator may publish the trial results, subject to prior written consent from ACME-1. ACME-1 will not unreasonably withhold such consent. ACME-1 must be acknowledged in all publications.

Use of Data

Docupal Demo, LLC agrees not to use the clinical trial data for any purpose other than conducting the clinical trial as outlined in this Agreement. Docupal Demo, LLC will not disclose the data to any third party without ACME-1's prior written consent. ACME-1 has the right to use the data for regulatory submissions, further research, and commercial purposes.

Confidentiality

All data, results, and inventions will be treated as confidential information. Both parties will protect the confidentiality of this information. This obligation survives the termination of this Agreement. Specific terms regarding confidentiality are further detailed in the Confidentiality section of this Agreement.

Patents

ACME-1 has the sole right to seek patent protection for any inventions or discoveries arising from the clinical trial. Docupal Demo, LLC agrees to assist ACME-1 in securing such patent protection. This includes providing necessary documentation and assistance as reasonably requested by ACME-1.

+123 456 7890
+123 456 7890
info@website.com
websitename.com
P.O. Box 283 Demo
Frederick, Country

Investigator's Rights

The Investigator retains the right to use the clinical trial data for academic and research purposes, provided that ACME-1's prior written consent is obtained. Such consent will not be unreasonably withheld. The Investigator will appropriately acknowledge ACME-1's ownership of the data in any such use.

Publication and Communication

Publication Rights

DocuPal Demo, LLC will submit any proposed publication or presentation of the clinical trial results to ACME-1 for review and approval prior to submission. ACME-1's approval will not be unreasonably withheld. This review is to ensure the protection of ACME-1's proprietary information and to allow for timely filing of patent applications, if applicable.

Authorship

Authorship of any publications arising from the clinical trial will be determined by mutual agreement of DocuPal Demo, LLC and ACME-1. Disputes regarding authorship will be resolved through good faith negotiation. If the parties cannot reach an agreement, the dispute will be submitted to binding arbitration as outlined in the "Dispute Resolution" section of this Agreement.

Communication Protocol

DocuPal Demo, LLC will maintain regular communication with ACME-1 regarding the progress of the clinical trial. This includes, but is not limited to:

- Providing ACME-1 with regular progress reports, at least [specify frequency, e.g., monthly or quarterly].
- Promptly notifying ACME-1 of any significant deviations from the study protocol.
- Informing ACME-1 of any serious adverse events (SAEs) or unanticipated problems involving risks to human subjects, as required by applicable regulations and guidelines.
- Responding to ACME-1's inquiries in a timely manner.

+123 456 7890
+123 456 7890
info@website.com
websitename.com
P.O. Box 283 Demo
Frederick, Country

ACME-1 will designate a primary contact person for communication with DocuPal Demo, LLC. DocuPal Demo, LLC will also designate a primary contact person. All formal communications related to this Agreement will be directed through these designated contacts.

Data Sharing

DocuPal Demo, LLC will provide ACME-1 with access to the clinical trial data as specified in the "Data Ownership and Usage" section of this Agreement. Any sharing of data with third parties will require the prior written consent of both DocuPal Demo, LLC and ACME-1.

Public Statements

Neither party will make any public statements regarding the clinical trial or its results without the prior written consent of the other party, except as required by law or regulation. This includes press releases, presentations at conferences, and publications in scientific journals.

Liability and Indemnification

Acme, Inc. Indemnification

ACME-1 shall indemnify, defend, and hold harmless DocuPal Demo, LLC, its officers, directors, employees, and agents from and against any and all claims, losses, damages, liabilities, costs, and expenses (including reasonable attorneys' fees) arising out of or resulting from:

- The use of the investigational drug in the clinical trial.
- Any adverse events related to the investigational drug.
- The breach of any representation or warranty made by ACME-1 in this Agreement.
- The negligence or willful misconduct of ACME-1, its employees, or agents.

This indemnification shall survive the termination of this Agreement.

+123 456 7890
+123 456 7890
info@website.com
websitename.com
P.O. Box 283 Demo
Frederick, Country

DocuPal Demo, LLC Indemnification

DocuPal Demo, LLC shall indemnify, defend, and hold harmless ACME-1, its officers, directors, employees, and agents from and against any and all claims, losses, damages, liabilities, costs, and expenses (including reasonable attorneys' fees) arising out of or resulting from:

- The breach of any representation or warranty made by DocuPal Demo, LLC in this Agreement.
- The negligence or willful misconduct of DocuPal Demo, LLC, its employees, or agents.

This indemnification shall survive the termination of this Agreement.

Limitations of Liability

Neither party shall be liable to the other for any indirect, incidental, consequential, special, or punitive damages arising out of or relating to this Agreement, whether based on contract, tort, or any other legal theory, even if such party has been advised of the possibility of such damages.

DocuPal Demo, LLC's liability under this Agreement shall be limited to the total amount of compensation paid by ACME-1 to DocuPal Demo, LLC under this Agreement.

Insurance

ACME-1 shall maintain, at its own expense, clinical trial insurance with coverage limits sufficient to cover potential liabilities arising from the clinical trial, including product liability and participant injury. ACME-1 will provide DocuPal Demo, LLC with a certificate of insurance evidencing such coverage.

DocuPal Demo, LLC shall maintain, at its own expense, professional liability insurance with coverage limits sufficient to cover potential liabilities arising from its performance of the clinical trial. DocuPal Demo, LLC will provide ACME-1 with a certificate of insurance evidencing such coverage.

+123 456 7890
+123 456 7890
info@website.com
websitename.com
P.O. Box 283 Demo
Frederick, Country

Reporting

Each party shall promptly notify the other party of any claim or potential claim that may give rise to indemnification under this Agreement. The indemnified party shall cooperate fully with the indemnifying party in the defense of any such claim. The indemnifying party shall have the right to control the defense of any such claim, including the selection of counsel, subject to the indemnified party's right to participate in the defense at its own expense.

Term and Termination

This Agreement will start on the Effective Date and will continue until the Clinical Trial is completed, unless it is terminated earlier as described below.

Termination

Either DocuPal Demo, LLC or ACME-1 may terminate this Agreement with 30 days written notice to the other party.

Grounds for Termination by DocuPal Demo, LLC

DocuPal Demo, LLC can terminate this Agreement if ACME-1:

- Breaches any material term of this Agreement, and fails to correct the breach within 30 days of receiving written notice.
- Raises safety concerns related to the Clinical Trial or the drug under investigation.
- Fails to comply with relevant regulatory requirements.

Grounds for Termination by ACME-1

ACME-1 can terminate this Agreement if DocuPal Demo, LLC:

- Breaches any material term of this Agreement, and fails to correct the breach within 30 days of receiving written notice.
- Raises safety concerns related to the Clinical Trial conduct.
- Fails to comply with relevant regulatory requirements.

+123 456 7890
+123 456 7890
info@website.com
websitename.com
P.O. Box 283 Demo
Frederick, Country

Effects of Termination

Upon termination of this Agreement:

- ACME-1 will receive all data collected during the Clinical Trial up to the termination date.
- ACME-1 will make a final payment to DocuPal Demo, LLC for all services performed and expenses incurred up to the termination date, as per the payment schedule outlined in this Agreement.
- DocuPal Demo, LLC will return to ACME-1 any unused supply of the drug provided for the Clinical Trial.

Survival of Obligations

Certain obligations will continue even after this Agreement terminates. These include:

- Confidentiality obligations
- Indemnification obligations
- Data privacy obligations
- Data integrity obligations
- Publication rights as defined in this Agreement.

Dispute Resolution

DocuPal Demo, LLC and ACME-1 will work to resolve any disputes quickly and efficiently. Both parties agree to the following steps to address disagreements related to this Clinical Trial Agreement.

Initial Negotiation

First, both parties will attempt to resolve any dispute through good-faith negotiation. This involves direct discussions between designated representatives from DocuPal Demo, LLC and ACME-1. The representatives will have the authority to settle the dispute. This negotiation period will last for [Number] days unless both parties agree to extend it.

+123 456 7890
+123 456 7890
info@website.com
websitename.com
P.O. Box 283 Demo
Frederick, Country

Mediation

If negotiation fails to resolve the dispute, both parties agree to submit the matter to mediation. A mutually agreed-upon mediator will be selected. If the parties cannot agree on a mediator, they will seek assistance from [Organization, e.g., American Arbitration Association] to appoint one. The mediation will take place in [City, State] or another location agreed upon by both parties. Both parties will share the costs of the mediation equally.

Arbitration

If mediation is unsuccessful, the dispute will be settled by binding arbitration. The arbitration will be conducted in accordance with the rules of [Arbitration Organization, e.g., American Arbitration Association]. A single arbitrator will be selected by mutual agreement of both parties. If both parties cannot agree on an arbitrator, the selection will be made by [Arbitration Organization, e.g., American Arbitration Association]. The arbitration will take place in [City, State] or another location agreed upon by both parties. The arbitrator's decision will be final and binding on both parties. The costs of arbitration, including arbitrator fees, will be shared equally by both parties, unless the arbitrator determines otherwise.

Governing Law and Jurisdiction

This Clinical Trial Agreement is governed by and interpreted in accordance with the laws of the State of Delaware, without regard to its conflict of laws principles. Any legal action arising out of or relating to this Agreement will be brought in the state or federal courts located in Delaware, and both parties consent to the jurisdiction and venue of such courts.

Regulatory Compliance and Ethics

DocuPal Demo, LLC and ACME-1 will conduct the clinical trial in accordance with all applicable laws and regulations. These include, but are not limited to, the regulations and guidelines set forth by the United States Food and Drug Administration (FDA). Both parties will also adhere to the International Council for Harmonisation (ICH) guidelines for Good Clinical Practice (GCP).

+123 456 7890
+123 456 7890
info@website.com
websitename.com
P.O. Box 283 Demo
Frederick, Country

Ethical Conduct

The clinical trial will be conducted according to the ethical principles outlined in the Declaration of Helsinki. Prior to the commencement of the trial, the study protocol and informed consent form will be submitted to and approved by an Institutional Review Board (IRB) or Ethics Committee (EC) at each participating site. The Sponsor, ACME-1, is responsible for securing and maintaining these approvals throughout the duration of the trial. Any modifications to the protocol or informed consent will also require IRB/EC approval before implementation.

Compliance Monitoring

ACME-1 will monitor the clinical trial to ensure compliance with the protocol, GCP guidelines, and all relevant regulatory requirements. DocuPal Demo, LLC will facilitate this monitoring process. Monitoring activities may include on-site visits to clinical trial sites, review of study documents, and verification of data.

Audits and Inspections

Both parties acknowledge that regulatory authorities, such as the FDA, may conduct audits or inspections of the clinical trial. DocuPal Demo, LLC agrees to cooperate fully with any such audits or inspections and to provide access to all relevant documents and personnel. ACME-1 will notify DocuPal Demo, LLC promptly of any planned or conducted audits or inspections.

Reporting

DocuPal Demo, LLC will submit regular progress reports to ACME-1, detailing the status of the clinical trial, including enrollment numbers, data quality, and any deviations from the protocol. ACME-1 is responsible for reporting any serious adverse events (SAEs) or suspected unexpected serious adverse reactions (SUSARs) to the appropriate regulatory authorities in accordance with applicable regulations. Furthermore, DocuPal Demo, LLC will report any potential breaches of data integrity or privacy to ACME-1 immediately upon discovery. ACME-1 will then take appropriate action as required by applicable regulations.

+123 456 7890
+123 456 7890
info@website.com
websitename.com
P.O. Box 283 Demo
Frederick, Country

Data Integrity

Both parties will ensure the integrity and security of all data generated during the clinical trial. This includes implementing appropriate data management procedures, maintaining accurate and complete records, and protecting against unauthorized access or modification of data. All electronic data will be stored in a secure, validated system with audit trails.

Training

All personnel involved in the clinical trial will be adequately trained on the protocol, GCP guidelines, and relevant regulatory requirements. DocuPal Demo, LLC will maintain records of all training provided.

Record Retention

DocuPal Demo, LLC will maintain all essential documents related to the clinical trial for the time period specified in applicable regulations or as otherwise agreed upon in writing with ACME-1, ensuring compliance with record retention requirements.

Data Management and Access

Data Collection and Monitoring

DocuPal Demo, LLC will collect clinical trial data according to the protocol outlined in this Agreement. Data collection methods will comply with Good Clinical Practice (GCP) guidelines and applicable regulatory requirements. We will use validated data collection systems. These systems will ensure data accuracy and reliability. DocuPal Demo, LLC will implement data monitoring procedures. These procedures will identify and address any data discrepancies or inconsistencies.

Data Ownership

Acme, Inc. retains all right, title, and interest in and to all data arising from the clinical trial. This includes, but is not limited to, raw data, processed data, and analyses. DocuPal Demo, LLC will treat all data as confidential information of Acme, Inc. We will only use the data as specified in this Agreement.

+123 456 7890
+123 456 7890
info@website.com
websitename.com
P.O. Box 283 Demo
Frederick, Country

Data Access Rights

Acme, Inc. has the right to access all clinical trial data. This access includes the right to review, copy, and analyze the data. DocuPal Demo, LLC will provide Acme, Inc. with access to the data in a timely manner. The format will be mutually agreed upon.

Data Auditing

Acme, Inc. has the right to audit DocuPal Demo, LLC's data management practices and systems. This audit can assess compliance with this Agreement and applicable regulations. DocuPal Demo, LLC will cooperate fully with any such audit. This includes providing access to relevant documents, systems, and personnel.

Data Integrity

DocuPal Demo, LLC will ensure the integrity of the clinical trial data. We will achieve this through validated systems and standard operating procedures (SOPs). These SOPs will cover data entry, data validation, data storage, and data security. DocuPal Demo, LLC will maintain an audit trail of all data changes. We will also implement appropriate security measures to prevent unauthorized access, modification, or destruction of the data.

Amendments and Notices

Amendments

This Agreement may be amended by mutual written agreement of DocuPal Demo, LLC and ACME-1. Any such amendment must be in writing. It must be signed by authorized representatives of both parties to be effective.

Notices

General Communication

All notices and other communications relating to this Agreement must be in writing. Notices can be sent by email or certified mail.

+123 456 7890
+123 456 7890
info@website.com
websitename.com
P.O. Box 283 Demo
Frederick, Country

Sending Notices

All notices to DocuPal Demo, LLC should be sent to:

Docupal Demo, LLC 23 Main St, Anytown, CA 90210 United States

All notices to ACME-1 should be sent to:

Acme, Inc 3751 Illinois Avenue, Wilsonville, Oregon - 97070 USA

Effective Date of Notices

Notices delivered by certified mail will be considered effective five (5) business days after mailing. Notices sent by email will be considered effective on the date sent, provided that receipt is acknowledged by the recipient.

Signatures and Execution

This Clinical Trial Agreement becomes effective on the date of the last signature, indicating full acceptance of the terms and conditions outlined within.

Signatures

DocuPal Demo, LLC

Signature:	
Name:	
Title:	
Date:	August 9, 2025

Acme, Inc (ACME-1)

Signature:	
Name:	
Title:	
Date:	

+123 456 7890
+123 456 7890
info@website.com
websitename.com
P.O. Box 283 Demo
Frederick, Country

Execution

Each party acknowledges that by signing this Agreement, they have read, understood, and agreed to all provisions. Both DocuPal Demo, LLC and Acme, Inc (ACME-1) commit to fulfilling their respective obligations as described herein. This agreement is executed as of the dates written above.

+123 456 7890
+123 456 7890
info@website.com
websitename.com
P.O. Box 283 Demo
Frederick, Country